The cells responsible for your grip strength don’t live in your arms. Some of them, it turns out, live in your gut.
That’s the upshot of a study published this week in the journal Gut, and it’s a stranger finding than it might first appear. Researchers in the Netherlands and Spain have identified a specific species of gut bacterium, Roseburia inulinivorans, that correlates with muscle strength in both young and older adults, and that demonstrably increases grip strength in mice when administered orally. Not exercise. Not protein supplements. A microbe. The same kind of thing your digestive tract uses to ferment dietary fibre.
The gut microbiome has been implicated in a remarkable range of health conditions over the past decade or so, from metabolic disease to neurodegeneration to cardiovascular risk to mood disorders, and there has been growing interest in whether it might influence muscle mass and function too. What’s been missing is specificity. The general claim that gut bacteria matter for muscle health is not quite the same as naming the species responsible, describing what it does mechanically, and showing a causal effect in a controlled experiment. This study attempts all three.
The human data came from 123 participants across two Spanish cohorts: 90 young adults aged 18 to 25, and 33 older adults aged 65 and over. Stool samples were analysed for bacterial composition; participants also had their handgrip strength measured, along with leg press and bench press performance and cardiorespiratory fitness. Within the Roseburia genus, the team tested four different species. Only one showed a consistent signal. In the older cohort, those with detectable R. inulinivorans had handgrip strength roughly 29% higher than those without, without any accompanying boost in aerobic capacity. In the younger adults, higher abundance of the bacterium was associated with both stronger grip and better cardiovascular fitness. The other Roseburia species either showed no association or weak and inconsistent links.
Correlation, of course, is not causation. The researchers were well aware of this. To test whether the bacterium was actually driving the muscle effects rather than merely co-occurring with physical fitness, they turned to mice. Thirty-two animals had their gut microbiomes depleted with a two-week course of antibiotics, then received either R. inulinivorans, one of two other Roseburia species, or a control solution, three times a week for eight weeks. By week four, the mice receiving R. inulinivorans had grip strength roughly 30 percent higher than the controls. By week eight, the difference held. The other bacteria produced no comparable effect.
What changed in the muscles? Quite a bit, as it turns out. The soleus muscle in treated mice showed a higher proportion of type II, or fast-twitch, fibres compared to controls. These are the fibres recruited for explosive, powerful movements (sprinting, lifting, sudden exertion) as opposed to the slow-twitch type I fibres that dominate endurance activity. The treated mice also had larger muscle fibres overall, with a pronounced skew toward the biggest fibre sizes.
Here is where the mechanism gets genuinely interesting, and also genuinely surprising. Roseburia species are well-known butyrate producers, and butyrate is a short-chain fatty acid with well-documented effects on gut health and metabolism. The obvious hypothesis was that R. inulinivorans was doing its work through butyrate. It wasn’t. Short-chain fatty acid levels in the gut were unchanged across all groups. Instead, the team found a pronounced depletion of amino acids in the caecum of treated mice, including methionine, leucine, isoleucine, alanine, valine and lysine. These are nutrients the bacterium appears to be competing for, consuming more than its share of the amino acids available in the gut lumen.
That sounds initially like bad news for the muscles. Less available amino acid in the gut should mean less building material for muscle protein synthesis. But the picture that emerged from metabolomics analysis of skeletal muscle tissue was the opposite. The muscles of R. inulinivorans-treated mice showed elevated activity in the purine pathway and the pentose phosphate pathway, two processes central to nucleotide production, redox balance and energy metabolism. It’s as if the muscles, confronted with a squeeze on the usual amino acid supply, were compensating by rerouting their energy metabolism. The upshot, in terms of fibre size and type, was net growth rather than atrophy.
Whether the same mechanism operates in humans is not yet established. The mouse model has real limitations: none of the human-derived Roseburia species colonised the mouse gut in any lasting way (they seem to clear within 24 hours of administration), which means the effects are probably mediated by transient metabolite signals rather than a stable microbial community. The antibiotic pre-treatment used to clear the native gut bacteria also complicates interpretation, since disrupting the whole microbiome affects host physiology in ways that go beyond simply making space for the introduced species. The human data, meanwhile, is cross-sectional, so the team can’t say whether higher R. inulinivorans levels cause better muscle function, or whether fitter, more active people happen to harbour more of the bacterium.
There’s also the question of where the bacterium goes with age. The team compared R. inulinivorans abundance across their young and older cohorts and found it was markedly lower in the over-65s, the very age group at highest risk of sarcopenia, the progressive muscle loss that contributes to frailty and falls. The decline appears to be specific to this species within the genus; the other Roseburia species showed no comparable age-related pattern. A meta-analysis of publicly available metagenomic datasets broadly supported this trend, though the effect didn’t reach statistical significance when all cohorts were pooled.
What the team propose, tentatively, is that R. inulinivorans might eventually be developed as a probiotic intervention, perhaps targeting older adults or people with chronic conditions associated with muscle wasting. It’s absent in individuals with sarcopenia, according to other cited work, and Roseburia as a genus is depleted in conditions including cerebral palsy, anorexia nervosa and cancer cachexia. Interestingly, resistance training in young adults has previously been shown to increase Roseburia abundance by roughly 2%, which raises the possibility of a feedback loop: exercise promotes the bacterium, which may promote further muscle adaptation, which makes exercise easier.
Human clinical trials testing oral supplementation with R. inulinivorans don’t yet exist. Before this paper, the species barely registered in the muscle science literature. Whether the grip-strength effects seen in antibiotic-depleted mice would translate to the far messier ecology of the human gut is, honestly, unknown. But the question is now, at minimum, worth asking.
DOI / Source: https://doi.org/10.1136/gutjnl-2025-336980
Frequently Asked Questions
R. inulinivorans is an anaerobic bacterium that lives in the human large intestine, where it ferments dietary fibre. It’s part of the broader Roseburia genus, a group of gut microbes known mainly for producing butyrate, a short-chain fatty acid with various health effects. The bacterium is present in most healthy adults but varies considerably in abundance, and appears to decline with age.
This is the counterintuitive part. The bacterium seems to consume a relatively large share of available amino acids in the gut lumen, reducing what reaches the bloodstream. The muscle tissue then appears to compensate by ramping up activity in the purine and pentose phosphate pathways, metabolic routes that support energy production and nucleotide synthesis. The net effect in mice was larger, stronger muscle fibres, though how or whether this translates to humans is not yet clear.
Not meaningfully. Commercial probiotic products containing R. inulinivorans don’t currently exist in clinical-grade formulations, and no human trials have tested its effects on muscle strength. The mouse study is encouraging but uses a highly artificial model (antibiotic-depleted gut, no stable colonisation). The researchers themselves describe it as a candidate for future nutraceutical development rather than an existing intervention.
Partly, perhaps, but the relationship runs in both directions. Strength training has previously been shown to increase Roseburia abundance by around 2%, suggesting muscle activity itself may promote the very bacterium linked to muscle function. Diet also shapes which gut microbes thrive. The gut microbiome is not fixed; it responds to what you eat, how much you move, medications you take, and many other factors.
The study doesn’t establish a direct molecular link between R. inulinivorans and fibre type specifically. The shift toward type II fibres observed in mice likely follows from the broader metabolic changes the bacterium induces: alterations in amino acid handling and activation of the pentose phosphate pathway in muscle. Whether the fibre-type shift is a direct consequence of those pathways or a downstream effect of overall muscle growth remains an open question.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.
Key Takeaways
- A study reveals the gut bacterium Roseburia inulinivorans boosts grip strength in humans and mice.
- Researchers found a correlation between R. inulinivorans and stronger muscle function, particularly in older adults.
- Mice treated with R. inulinivorans showed increased grip strength and larger fast-twitch muscle fibers.
- The bacterium consumes amino acids, yet leads to muscle growth by altering metabolic pathways.
- Future probiotic interventions could target R. inulinivorans to combat muscle loss in aging populations.
As the main author, I am impressed by the accuracy of your interpretations. Congratulations!
Cheers, Borja! Congratulations on the fascinating work. I’ve paid a little attention to bacteria targeting obesity (l reuteri, specifically) but this is the other side of the coin of body composition. Well done!